Feasibility of a Randomized Cluster Trial for Blood Pressure Targets in In-centre Hemodialysis Units
Opening soon NCT06695611
Run by University of Manitoba · for 18 and older · All sexes
What this study is about
High blood pressure in people receiving hemodialysis is known to contribute to heart disease and heart-related death from strokes, heart failure, left ventricular hypertrophy (which is a thickening of the heart wall that makes it difficult for the heart to pump blood) and arrythmias (an irregular or abnormal heartbeat). In comparison, low blood pressure can lead to cramps, myocardial stunning, and cerebrovascular ischemia. However, despite, blood pressure management being an important component of hemodialysis care, the "best" blood pressure target for people on hemodialysis is unknown. Finding the "right" blood pressure to target can have a major impact on patient lives. We are proposing a large, pragmatic, cluster randomized trial targeting a lower versus higher blood pressure target in in-centre hemodialysis units in Canada. Our initial steps towards this bigger trial are to run a smaller trial including 4 units, to evaluate whether it is feasible to conduct a larger trial. Our ultimate goal is to deliver the definitive randomized trial for blood pressure targets in the hemodialysis population.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age > 18 years old
- Undergoing in-centre hemodialysis at least twice weekly
- > 90 days since initiation of dialysis
🚫 You may not be able to join if…
- Participation in another intervention study that may affect blood pressure other than other cluster RCTs of dialysate composition
- Inability to measure blood pressures in an upper arm
- Pregnancy, anticipated pregnancy, or breastfeeding
- Unmeasurable SBP (e.g., have left ventricular assist device)
- Life expectancy < 4 months
- Planned transition to home dialysis within 3 months
- Planned move to a different dialysis unit within 3 months
- Anticipated living donor kidney transplant within 3 months
- Other reasons as determined by treating clinician, reasons will be recorded
Where this trial is running
- University of Manitoba, Winnipeg, Manitoba, Canada
Who to contact
Rachel Girimonte, MSc · 204-632-3667 · rgirimonte@sogh.mb.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06695611.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.